Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 50 15 versus RAMIPRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 50 15 versus RAMIPRIL.
CAPOZIDE 50/15 vs RAMIPRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAPOZIDE 50/15 combines captopril (angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (thiazide diuretic). Captopril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- cotransporter in distal convoluted tubules.
Ramipril is a prodrug that is hydrolyzed in the liver to its active metabolite ramiprilat, which inhibits angiotensin-converting enzyme (ACE), thereby decreasing angiotensin II production, reducing vasoconstriction, aldosterone secretion, and sodium retention.
Oral, 1 tablet (captopril 50 mg / hydrochlorothiazide 15 mg) once daily. May increase to 2 tablets daily in divided doses if needed.
Initial: 2.5 mg orally once daily; Maintenance: 2.5-20 mg/day in 1-2 divided doses; Maximum: 20 mg/day.
None Documented
None Documented
Clinical Note
moderateRamipril + Torasemide
"The risk or severity of adverse effects can be increased when Ramipril is combined with Torasemide."
Clinical Note
moderateRamipril + Etacrynic acid
"The risk or severity of adverse effects can be increased when Ramipril is combined with Etacrynic acid."
Clinical Note
moderateRamipril + Furosemide
"The risk or severity of adverse effects can be increased when Ramipril is combined with Furosemide."
Clinical Note
moderateRamipril + Bumetanide
Captopril: terminal half-life ~2 hours (in patients with normal renal function; prolonged in renal impairment to 21-36 hours). Hydrochlorothiazide: half-life 6-15 hours (mean ~9 hours; prolonged in renal impairment). Clinical context: dosing interval affected by renal function.
Terminal half-life of ramiprilat is 13–17 hours (prolonged to 50 hours in renal impairment). Accumulation half-life is 110 hours after multiple doses.
Captopril: renal excretion of unchanged drug and metabolites, primarily in urine (60-75%), with ~20% as unchanged captopril; small amount in feces (5-10%). Hydrochlorothiazide: renal excretion (95% unchanged), <5% via biliary/fecal.
Primarily renal (60% as unchanged drug and metabolites) and fecal (40% via biliary elimination).
Category C
Category D/X
ACE Inhibitor and Diuretic Combination
ACE Inhibitor
"The risk or severity of adverse effects can be increased when Ramipril is combined with Bumetanide."